Drug Trial Radar · NCT01939002
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
Last checked: Nov 20, 2026Latest source record: Jan 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Nov 2013
Primary completion
Oct 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Sep 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the proportion of participants with relapsing multiple sclerosis who experience new and/or increased flu-like symptoms (FLS) after transitioning from nonpegylated IFN-β therapies to peginterferon beta-1a (BIIB017). Secondary objectives are: to determine the severity and frequency (measured by flu-like symptom score \[FLS-S\]) of FLS in these participants; to determine the duration (measured in number of hours) of FLS in these participants; to determine the effect of BIIB017 on other participant-reported outcomes, including treatment satisfaction (measured with the Treatment Satisfaction Questionnaire for Medication \[TSQM\]) and disability status (measured with the Patient Determined Disease Steps \[PDDS\]) over a 56-week period; to determine whether interferon-related FLS result in missed days of work/daily activities (e.g., absenteeism); to assess the use of additional medications (in addition to current medications used to treat FLS) to relieve BIIB017-related FLS; to determine the incidence of adverse events throughout the study period; to characterize the immunogenicity profiles of participants switching from prior IFN-β therapy to BIIB017.
Conditions
- Relapsing Multiple Sclerosis
Interventions
BIIB017Drug
naproxenDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall PopulationTime frame: during the first 8 weeks of treatment
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Boulder, Colorado
Research Site
Fort Collins, Colorado
Research Site
Dover, Delaware
Research Site
Newark, Delaware
Research Site
Jacksonville, Florida
Research Site
Melbourne, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Kansas City, Kansas
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Boston, Massachusetts
Research Site
Lexington, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Detroit, Michigan
Research Site
Chesterfield, Missouri
Research Site
St Louis, Missouri
Research Site
Great Falls, Montana
Research Site
Lincoln, Nebraska
Research Site
Latham, New York
Research Site
Plainview, New York
Research Site
Asheville, North Carolina
Research Site
Akron, Ohio
Research Site
Dayton, Ohio
Research Site
Uniontown, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Portland, Oregon
Research Site
Greenville, South Carolina
Research Site
Franklin, Tennessee
Research Site
Knoxville, Tennessee
Research Site
Salt Lake City, Utah
Research Site
Newport News, Virginia
Research Site
Roanoke, Virginia
Research Site
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.